Clinical Trials
123 trialsA Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
MK-3475-01F
Merck Sharp & Dohme LLC
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines, Inc.
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
University of Chicago
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
BOE Technology Group Co., Ltd.
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
M.D. Anderson Cancer Center
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
KontRASt-03
Novartis
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
KontRASt-R
Novartis
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Revolution Medicines, Inc.
HERKULES-3
Erasca, Inc.
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Allist Pharmaceuticals, Inc.
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
D3 Bio (Wuxi) Co., Ltd
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Sanofi
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Jacobio Pharmaceuticals Co., Ltd.
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
HAMMER
Synthorx, Inc, a Sanofi company
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
Genfleet Therapeutics (Shanghai) Inc.
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Chang Gung Memorial Hospital
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
Sun Yat-sen University
A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
Genfleet Therapeutics (Shanghai) Inc.
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Sanofi
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
Bristol-Myers Squibb
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Sun Yat-sen University
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
Nektar Therapeutics
AK129 Combination Therapy for Advanced Solid Tumors
Akeso
C-PRECISE-01
Menarini Group
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Study to Evaluate D-1553 in Subjects With Solid Tumors
InventisBio Co., Ltd
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
ImmunityBio, Inc.
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
ImmunityBio, Inc.
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
ImmunityBio, Inc.
MODULATE
Immodulon Therapeutics Ltd
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.